GLUEMonte Rosa Therapeutics, Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−39% vs 200-day) and a crowded short (+23% of shares).
In a downtrend, below its 50- and 200-day averages. Price is −39% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 22, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How GLUE is trading
Monte Rosa Therapeutics, Inc. is +5.0% over the past year while the S&P 500 is +16%: 11 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −39%
vs 200-day average · a clear downtrend
- RSI (14)
- 56
RSI (14) · neutral
- Below its 52-week high
- 57%
Below its 52-week high
Details›
- Last close2026-10-23
- $10.83
- 1 monthS&P 500 −0.94%
- −7.8%
- 1 yearS&P 500 +16%
- +5.0%
- 5 yearsS&P 500 +86%
- −44%
- vs 50-day average$12.56
- −14%
- 52-week high
- $25.31
- 52-week low
- $9.35
- Annualised volatility
- 109%
- Insider selling, net, 6 monthsForms 3/4/5 to 2026-10-22
- $632K
| Year | Return |
|---|---|
| 2026 (year to date) | −31% |
| 2025 | +126% |
| 2024 | +23% |
| 2023 | −26% |
| 2022 | −63% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 1 of 5 | −4.0% |
| Feb | 5 | 2 of 5 | −3.2% |
| Mar | 5 | 2 of 5 | +2.9% |
| Apr | 5 | 2 of 5 | −13% |
| May | 5 | 2 of 5 | −0.19% |
| Jun | 5 | 3 of 5 | +7.9% |
| Jul | 6 | 4 of 6 | +4.4% |
| Aug | 6 | 2 of 6 | +2.1% |
| Sep | 6 | 2 of 6 | −4.5% |
| Oct | 6 | 4 of 6 | +19% |
| Nov | 5 | 2 of 5 | +2.8% |
| Dec | 5 | 2 of 5 | +8.3% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.